ScreenerHero
BIOA-BBioArctic AB (publ)
STO · SE · Healthcare · Biotechnology · bioarctic.se
335.60SEK-0.47%Mkt Cap: 2.85B $P/E: 140.42

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medic…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap2.85B $
Enterprise Value2.67B $
Revenue (TTM)109.72M $
Gross Profit185.56M $
Net Income (TTM)97.79M $
Revenue/Share1.239 USD
Last Price335.60 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees141
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)140.42
P/E (Forward)114.83
PEG—
EV/EBITDA—
EV/Revenue24.34
P/S25.76
P/B13.44
EPS (TTM)2.38
EPS (Forward)2.90
52W Range
231.0078% of range364.40
52W High364.40 SEK
52W Low231.00 SEK
Profitability
Gross Margin97.04%
Oper. Margin45.92%
EBITDA Margin0.00%
Profit Margin51.14%
ROE51.97%
ROA39.70%
Growth
Revenue Growth-66.10%
Earnings Growth-79.30%
Cash Flow & Leverage
Operating CF136.88M $
CapEx (TTM)979.77K $
FCF Margin109.74%
FCF Yield4.23%
Net Debt-190.72M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.02
Current Ratio6.54
Quick Ratio5.12
Book Value/Sh24.77 SEK
Cash/Share22.93 SEK
Dividends
Fwd Div Rate2.000 SEK
Trail. Div Rate2.000 SEK
Div. Yield0.60%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateMay 29, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)316.75 SEK
Upside (mean)-5.6%
Target Range280.00 SEK – 363.00 SEK
SEK280.00-5.6% to meanSEK363.00
# Analysts4
Ownership
Shares Out.74.32M
Float54.40M
Insiders42.68%
Institutions35.50%
Technical
SMA 50314.35 (+6.8%)
SMA 200315.84 (+6.3%)
Beta-0.68
S&P 52W Chg18.16%
Avg Vol (30d)108.73K
Avg Vol (10d)101.67K
Technical Indicators
RSI (14)63.6
MACD3.9106
MACD Signal1.8820
MACD Hist.+2.0286
BB Upper335.24 SEK
BB Middle318.18 SEK
BB Lower301.12 SEK
BB Width10.72%
ATR (14)11.15 SEK
Vol Ratio (20d)1.16x